跳至主要内容
临床试验/DRKS00029024
DRKS00029024已完成2 期

Delving in the behavioural and neural correlates of pain perception using a therapy combining mindfulness meditation and transcranial direct current stimulation for the treatment of fibromyalgia syndrome. - Med_tDCS_Fibro

niversitätsmedizin Göttingen0 个研究点目标入组 44 人开始时间: 2022年5月31日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
30 Years 至 75 Years(—)
性别
All

入选标准

  • 1. Stable disease for at least 6 months prior to participation
  • 2. No new treatment approaches over the preceding 3 months
  • 3.Stable allowed fibromyalgia related medications (see below) for = 4 weeks prior to the
  • study. List of allowed medications:
  • -Intake of NSAIDs and coxibs as required (bei Bedarf), but participants must not take it 24
  • hours prior to study visits.
  • - Commonly used antidepressants for FMS will be allowed.
  • -Low dose (<25 mg THC content/day) of medical oromucosal cannabinoid therapy (e.g.
  • dronabinol, nabiximols, extracts). The participant has to refrain from taking it up to 24 hours
  • prior to study visits.
  • -Corticosteroids for comorbid conditions if the dose was constant within the last four
  • weeks before baseline and if the dose will likely remain constant for the duration of this trial.

排除标准

  • 1. Treatment with any of the following medications:
  • - Strong opioids, or taking more than three medications for fibromyalgia symptom relief.
  • - Carbamazepine, benzodiazepines, phenytoin, gabapentin, pregabalin; calcium channel
  • antagonists (e.g. flunarizine), NMDA receptor antagonists (e.g. dextromethorphan, memantine),
  • anticholinergics.
  • - Therapeutic local anesthetic infiltration of the spinal column within the last 4 weeks
  • before baseline and/or planned during the trial period.
  • - Topically administered medication with influence on the study target during the study
  • Inhaled or smoked cannabinoids for medical use.
  • 2. presence of any major, acute or unstable medical, neurological or psychiatric disorder,
  • diagnosis of severe or uncontrolled comorbid rheumatic disease, non-treated tumors, ongoing
  • chemo- or radiation therapy, clotting disorders or anticoagulant therapy
  • 3. Chronic migraine (at least 15 headache days/months, with at least 8 fulfilling criteria for
  • 4. Alcohol/drug addiction, abuse of any substance (except nicotine and caffeine) currently
  • and/or within the last 12 months prior to randomization
  • 5. Pregnancy or breastfeeding
  • 6. History of unexplained or repeated loss of consciousness
  • 7. Implanted metallic devices in head, neck or chest
  • 8. Participation in another scientific or clinical study within 12 weeks prior to study
  • 9. History of major surgery in the last three months
  • 10. Planned or ongoing pension proceedings
  • 11. Any planned surgery or inpatient treatment which might conflict with or influence the
  • participation or results of the study.
  • 12.History or suspicion of unreliability, poor co-operation or non-compliance with medical
  • 13. Mental condition, legal incapacity, and/or other circumstances rendering the patient
  • unable to understand the nature, scope and possible consequences of the study
  • 14. Acupuncture or chiropractic manipulations within the last 4 weeks before baseline
  • and/or during the trial.
  • 15.Formal meditation practice of high intensity

研究者

发起方
niversitätsmedizin Göttingen

相似试验